|
|
EVENITY® romosozumab Receives Approval In Japan for the Treatment of Osteoporosis In Patients at High Risk of FractureEVENITY® romosozumab Approved To Reduce The Risk Of Fractures And Increase Bone Mineral Density In Men And PostMenopausal Women With Osteoporosis At High Risk Of FractureRomosozumab in Japan is Being CoDeveloped Through a Strategic Alliance With Amgen Astellas BioPharma... See more |
|
| |
|
| |
|
|
Transparency notification UCB SA/NVNotification referring to situation on 31 December 2018Threshold crossed: 3%Latest holding: 2.88%Brussels Belgium, 8 January 2019 – 20:00 CET – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification with the... See more |
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.2 Notifications referring to situation on 26 and 27 December 2018Threshold crossed: 5%Latest holding: 5,03 %Brussels Belgium, 31 December 2018 – 20:00 CET – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2... See more |
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.2 Notifications referring to situation on 7 and 10 December 2018Threshold crossed: 5%Latest holding: 5.32%Brussels Belgium, 12 December 2018 – 20:00 CET – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency... See more |
|
| |
|
| |
|
|
UCB announces approval of VIMPAT® in ChinaVIMPAT® lacosamide now approved in China as adjunctive therapy in the treatment of partialonset seizures with or without secondary generalization in adult and adolescent patients 16 years of age and older with epilepsy.VIMPAT® will offer Chinese people living with epilepsy an additional treatment choice to support them in managing their... See more |
|
| |
|
| |
|
|
UCB and Amgen Announce FDA Advisory Committee Meeting to review EVENITY™ Romosozumab for the Treatment of Osteoporosis in Postmenopausal Women at High Risk for FractureBRUSSELS, Belgium, and THOUSAND OAKS, Calif. Nov. 30, 2018 – Amgen NASDAQ:AMGN and UCB Euronext Brussels: UCB today announced the U.S. Food and Drug Administration FDA Bone, Reproductive and Urologic Drugs Advisory Committee... See more |
|
| |
|
| |
|
|
Search :
